Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DCTH

Delcath Systems Inc

Sep 17 • 10:52AM ET

9.48

Dollar change -0.02
Percentage change -0.26	%

Healthcare • Medical Devices • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF IWC QQQS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.55	Insider Own	15.32%	Shs Outstand	28.00M	Perf Week	-4.00%
Market Cap	265.30M	Forward P/E	-	EPS next Y	-0.19	Insider Trans	1.27%	Shs Float	23.71M	Perf Month	26.33%
Income	-56.33M	PEG	-	EPS next Q	-0.22	Inst Own	31.51%	Short Float	5.90%	Perf Quarter	22.57%
Sales	11.88M	P/S	22.33	EPS this Y	54.48%	Inst Trans	-1.29%	Short Ratio	4.94	Perf Half Y	126.67%
Book/sh	0.15	P/B	63.13	EPS next Y	85.80%	ROA	-204.97%	Short Interest	1.40M	Perf Year	111.50%
Cash/sh	0.71	P/C	13.32	EPS next 5Y	15.00%	ROE	-2852.05%	52W Range	2.25 - 11.74	Perf YTD	127.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	64.26%	ROI	-1087.20%	52W High	-19.33%	Beta	0.80
Dividend TTM	-	Quick Ratio	2.04	Sales past 5Y	3.79%	Gross Margin	75.91%	52W Low	321.11%	ATR (14)	0.55
Dividend Ex-Date	-	Current Ratio	2.55	EPS Y/Y TTM	18.56%	Oper. Margin	-303.50%	RSI (14)	51.91	Volatility	4.27% 6.54%
Employees	76	Debt/Eq	1.33	Sales Y/Y TTM	350.44%	Profit Margin	-474.22%	Recom	1.00	Target Price	21.33
Option/Short	Yes / Yes	LT Debt/Eq	0.24	EPS Q/Q	16.16%	Payout	-	Rel Volume	0.84	Prev Close	9.50
Sales Surprise	50.62%	EPS Surprise	-32.67%	Sales Q/Q	1468.89%	Earnings	Aug 05 AMC	Avg Volume	282.77K	Price	9.48
SMA20	-1.20%	SMA50	9.30%	SMA200	57.80%	Trades		Volume	59,396	Change	-0.26%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-28-24	Initiated	Craig Hallum	Buy	$18
May-14-24	Initiated	Stephens	Overweight	$25
Jul-26-22	Resumed	Canaccord Genuity	Buy	$17
Dec-10-21	Initiated	H.C. Wainwright	Buy	$25
Mar-09-21	Initiated	Canaccord Genuity	Buy	$24
Jan-05-21	Initiated	BTIG Research	Buy	$23
Jun-01-20	Initiated	Laidlaw	Buy	$19

Sep-16-24 08:30AM	Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT in Metastatic Uveal Melanoma Subgroups (Business Wire)
Aug-28-24 04:01PM	Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients (Business Wire)
04:01PM	Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-27-24 08:30AM	Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients (Business Wire) +15.57%
Aug-26-24 04:01PM	Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors (Business Wire) +13.86%
08:30AM	Loading…
Aug-20-24 08:30AM	Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress (Business Wire)
Aug-12-24 04:01PM	Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-05-24 08:59PM	DCTH Stock Earnings: Delcath Systems Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
04:01PM	Delcath Systems Reports Second Quarter 2024 Results and Business Highlights (Business Wire)
08:30AM	Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT (Business Wire)
Jul-30-24 04:01PM	Delcath Systems to Participate in Upcoming Investor Conferences (Business Wire)
Jul-22-24 04:01PM	Delcath Systems to Host Second Quarter 2024 Earnings Call (Business Wire)
Jul-15-24 12:00PM	Delcath Systems, Inc. (DCTH) is a Great Momentum Stock: Should You Buy? (Zacks)
Jun-14-24 08:50AM	Here's What Could Help Delcath Systems (DCTH) Maintain Its Recent Price Strength (Zacks)
Jun-03-24 09:55AM	Does Delcath Systems (DCTH) Have the Potential to Rally 197.87% as Wall Street Analysts Expect? (Zacks)
09:30AM	Loading…
May-28-24 09:30AM	Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors (Business Wire) -5.53%
May-17-24 09:55AM	Wall Street Analysts Predict a 201.72% Upside in Delcath Systems (DCTH): Here's What You Should Know (Zacks) +8.76%
May-15-24 08:50AM	What Makes Delcath Systems (DCTH) a Good Fit for 'Trend Investing' (Zacks)
03:02AM	Delcath Systems Inc (DCTH) Q1 2024 Earnings Call Transcript Highlights: Key Financials and ... (GuruFocus.com)
May-14-24 11:52AM	DCTH Stock Earnings: Delcath Systems Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +30.93%
07:30AM	Delcath Systems Reports First Quarter 2024 Results and Business Highlights (PR Newswire)
May-07-24 08:30AM	Delcath Systems to Host First Quarter 2024 Earnings Call (PR Newswire)
May-06-24 09:00AM	Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT (PR Newswire)
May-03-24 05:15PM	Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-23-24 09:55AM	How Much Upside is Left in Delcath Systems (DCTH)? Wall Street Analysts Think 244.83% (Zacks)
Apr-05-24 09:55AM	Can Delcath Systems (DCTH) Climb 277.73% to Reach the Level Wall Street Analysts Expect? (Zacks)
Apr-04-24 08:35AM	Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-02-24 12:00PM	Delcath Systems (DCTH) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-27-24 11:50AM	Delcath Systems, Inc. (NASDAQ:DCTH) Q4 2023 Earnings Call Transcript (Insider Monkey) +10.41%
Mar-26-24 11:52AM	DCTH Stock Earnings: Delcath Systems Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
09:12AM	Loading…
09:12AM	Delcath Systems Inc (DCTH) Reports Mixed Year-End Financials Amidst Strategic Advancements (GuruFocus.com)
08:40AM	Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update (PR Newswire)
Mar-22-24 02:43PM	Hedge Fund and Insider Trading News: David Tepper, Ken Griffin, Starboard Value, ExodusPoint Capital, Elliott Management, Three Arrows Capital, Delcath Systems Inc (DCTH), Dell Technologies Inc (DELL), and More (Insider Monkey)
Mar-20-24 08:15AM	Delcath Systems Closes $7 Million Private Placement (PR Newswire)
Mar-19-24 09:00AM	Delcath Systems to Host Fourth Quarter and Full Year 2023 Results and Business Update Call (PR Newswire)
Mar-18-24 05:20PM	Delcath Systems Appoints Martha S. Rook as Chief Operating Officer (PR Newswire) +5.29%
Mar-15-24 08:20AM	Delcath Systems Announces $7 Million Private Placement (PR Newswire) +6.72%
Mar-08-24 05:00PM	Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:00AM	Delcath Systems to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-22-24 05:00PM	Delcath Systems Announces Healthcare Setting Locator for HEPZATO KIT (melphalan/Hepatic Delivery System) (PR Newswire)
Feb-16-24 05:00PM	Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-31-24 08:00AM	Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO (melphalan/Hepatic Delivery System) Effective April 1, 2024 (PR Newswire) +7.88%
Jan-23-24 08:00AM	Delcath Systems to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference (PR Newswire)
Jan-16-24 08:00AM	Delcath Systems Announces U.S. Launch and First Commercial Treatment Utilizing HEPZATO KIT (PR Newswire)
Jan-12-24 05:00PM	Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-15-23 01:02PM	Insider Buying: Chief Medical Officer Vojo Vukovic Acquires 40,000 Shares of Delcath Systems ... (GuruFocus.com)
Dec-07-23 09:00AM	Delcath Systems Announces Publication by Independent Investigators of a Retrospective Analysis of Quality of Life in the Journal Melanoma Research (PR Newswire)
Nov-15-23 05:00PM	Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-13-23 04:05PM	Delcath Systems Reports Third Quarter 2023 Results and Provides Business Update (PR Newswire) -24.50%
Nov-06-23 04:30PM	Delcath Systems to Host Third Quarter 2023 Results Call (PR Newswire)
Oct-16-23 08:30AM	Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers (PR Newswire) +6.07%
Oct-10-23 08:30AM	Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference (PR Newswire)
Oct-03-23 08:30AM	Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023 (PR Newswire)
Sep-27-23 04:05PM	Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-14-23 09:59AM	These 2 Strong Buy Penny Stocks Could Soar to $17 (Or Higher), Say Analysts (TipRanks)
Sep-11-23 08:00AM	A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting (PR Newswire)
Sep-05-23 04:00PM	Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023 (PR Newswire)
Sep-01-23 02:07PM	Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KIT (PR Newswire) +5.88%
Aug-29-23 08:00AM	Delcath Systems Announces an Independent Investigator Presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting (PR Newswire)
Aug-14-23 09:10PM	Delcath Systems, Inc. Announces FDA Approval of HEPZATO KIT for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma (PR Newswire) +81.73%
Aug-12-23 09:02AM	Delcath Systems, Inc.'s (NASDAQ:DCTH) Path To Profitability (Simply Wall St.)
Aug-09-23 05:33PM	Delcath Systems Reports Second Quarter 2023 Results and Provides Business Update (PR Newswire) -16.54%
Aug-03-23 08:30AM	Delcath Systems to File Its Second Quarter 2023 10-Q the Week of August 7 and Expects to Host a Conference Call the Following Week (PR Newswire)
Jun-21-23 04:10PM	Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.58%
Jun-20-23 08:30AM	Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer (PR Newswire) -5.72%
Jun-07-23 04:10PM	Delcath Systems Announces Sandra Pennell as Senior Vice President of Finance (PR Newswire)
May-12-23 08:00AM	Delcath Systems Provides Business Update and Reports Preliminary First Quarter 2023 Financial Results (PR Newswire)
May-09-23 09:00AM	Delcath Systems to Participate in the Lytham Partners Spring 2023 Investor Conference (PR Newswire)
May-03-23 08:30AM	Delcath Systems to Host First Quarter 2023 Results (PR Newswire)
Apr-03-23 04:30PM	Delcath Systems Announces Resumption of Interest-Only Period for Company's Debt Facility (PR Newswire)
Mar-29-23 09:41PM	Delcath Systems Announces Closing of Private Placement of up to $85 Million (PR Newswire) -6.42%
Mar-27-23 03:15PM	Why Delcath Systems Shares Are Jumping Today (Benzinga) +23.97%
08:20AM	Delcath Systems Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update (PR Newswire)
08:15AM	Delcath Systems Announces up to $85 Million Financing (PR Newswire)
08:10AM	Delcath Systems, Inc. Announces FDA Acceptance of New Drug Application Resubmission of Hepzato Kit with a PDUFA Date of August 14, 2023 (PR Newswire)
Feb-16-23 08:30AM	Delcath Announces Rotation of the Board of Directors Chairmanship; John R. Sylvester Appointed New Chairman as Company Prepares for US Commercial Launch (PR Newswire)
Feb-14-23 08:49AM	Delcath Systems Announces New Drug Application Resubmission for HEPZATO Kit (PR Newswire)
Jan-30-23 08:30AM	Delcath Systems to Participate at the BTIG MedTech, Digital Health, Life Sciences & Diagnostic Tools Conference on February 14 to 16 (PR Newswire)
Jan-17-23 08:00AM	Delcath Systems Announces Updated Results from CHOPIN Phase 1b Trial Published in Cardiovascular and Interventional Radiology (PR Newswire)
Dec-16-22 04:15PM	Delcath Systems Announces Inducement of Grant Under NASDAQ Listing Rule 5635(C)(4) (PR Newswire)
Dec-13-22 08:30AM	Delcath Systems Closes Private Placement of $6.2 Million (PR Newswire)
Dec-08-22 08:30AM	Delcath Systems Announces Private Placement of $6.2 Million (PR Newswire) +15.17%
Dec-05-22 09:00AM	Results of a Single Center Study on Delcath's CHEMOSAT® Hepatic Delivery System In the Treatment of Cholangiocarcinoma Published in the Journal Clinical & Experimental Metastasis (PR Newswire) -5.67%
Nov-09-22 04:15PM	Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-08-22 08:00AM	Delcath Systems Reports Third Quarter 2022 Results and Provides Business Update (PR Newswire) -7.00%
Oct-24-22 04:05PM	Delcath Systems to Host Third Quarter 2022 Results (PR Newswire)
Sep-01-22 04:15PM	Delcath Systems to Participate at the H.C. Wainwright 24th Annual Global Investor Conference on September 12 and 13, 2022 (PR Newswire)
Aug-08-22 07:45AM	Delcath Systems Reports Second Quarter 2022 Results and Provides Business Update (PR Newswire)
Aug-05-22 08:30AM	Results of a Multicenter Study on Delcath's CHEMOSAT® Hepatic Delivery System Published in Cardiovascular and Interventional Radiology (PR Newswire)
Jul-27-22 04:30PM	Delcath Systems to Host Second Quarter 2022 Results (PR Newswire)
04:15PM	Delcath Systems to Present at Upcoming Investor Conferences in August (PR Newswire)
Jul-20-22 04:10PM	Delcath Systems Closes Private Placement of $5.0 Million (PR Newswire) +10.00%
Jul-18-22 08:30AM	Delcath Systems Announces Private Placement of $5.0 Million (PR Newswire)
Jun-07-22 07:06AM	Delcath Systems Stock Jumps After Data Update From Eye Cancer Trials At ASCO Meeting (Benzinga) -8.44%
Jun-06-22 04:15PM	Positive Initial Results from CHOPIN Phase 1b Trial, FOCUS Trial Update and QoL Study Presented at the 2022 ASCO Annual Meeting (GlobeNewswire)
May-10-22 07:30AM	Delcath Systems Reports First Quarter 2022 Results and Provides Business Update (GlobeNewswire) -8.62%
May-09-22 08:30AM	Delcath Announces Poster Presentation at the 2022 ASCO Annual Meeting (GlobeNewswire)
May-02-22 03:02PM	Is Delcath Systems (NASDAQ:DCTH) Using Too Much Debt? (Simply Wall St.)
Apr-28-22 09:00AM	Delcath Systems to Host First Quarter 2022 Results (GlobeNewswire)

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded in August 1988 and is headquartered in Queensbury, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aharon Gil	Director	Mar 19 '24	Buy	3.72	26,882	100,001	1,069,710	Mar 20 08:00 PM
SALAMON STEVEN A J	Director	Mar 19 '24	Buy	3.72	26,882	100,001	1,121,025	Mar 20 07:44 PM
Vukovic Vojo	Chief Medical Officer	Dec 12 '23	Buy	3.00	40,000	120,000	100,000	Dec 14 04:20 PM
MICHEL GERARD J	Chief Executive Officer	Dec 08 '23	Buy	2.94	34,000	99,960	262,345	Dec 11 05:02 PM
Rosalind Advisors, Inc.	Director	Nov 17 '23	Buy	2.40	100,000	240,410	1,038,828	Nov 21 11:07 AM
Pennell Sandra	SVP of Finance, PFO and PAO	Nov 17 '23	Buy	2.43	30,000	72,900	30,000	Nov 21 07:42 AM
Vukovic Vojo	Chief Medical Officer	Nov 16 '23	Buy	2.48	60,000	148,800	60,000	Nov 20 04:22 PM
Hoffman David L.	See Remarks	Nov 16 '23	Buy	2.48	40,000	99,200	40,000	Nov 20 04:20 PM
Purpura John	Chief Operating Officer	Oct 13 '23	Buy	3.44	14,505	49,897	41,526	Oct 17 04:53 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

DCTH

Delcath Systems Inc

Upgrade your FINVIZ experience